2 insiders bought €497k of shares over the last 90 days, the latest filed 12 Oct 2026.
Fagron, founded in 2007, is a listed company based in Rotterdam, Netherlands. Its directors and officers file their transactions with FSMA. In the past year (18 October 2025 to 18 October 2026), 3 filings came from 3 insiders.
Both sides are active: 2 purchases worth €497k and 1 sale worth €565k, from 2 insiders and 1 insider respectively. Sales outweigh purchases by €69k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 board member and 1 senior executive. Pulido Andrew filed the largest sale, €565k, on 21 May 2026, which represents 0.031% of the company's market value.
With 3 filings in twelve months, the company is quieter than the median of 11 filings across the 77 companies we follow on the same exchange. Our records for Fagron go back to 2021, with 40 purchases and 13 sales on the open market in total.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase is recent: it was published 6 days ago, on 12 October 2026. The median gap between a trade and its publication by FSMA is 4 days. For comparison, MAR article 19 gives managers three business days to notify a trade.
This summary is built from FSMA disclosures alone and does not predict where the share price will go.
+1 other insider
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Fagron Strong Buy (bullish), based on 6 analysts. Average price target: €29.00.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 53 declarations
Fagron is a company specialized in the development and production of personalized medicines. It primarily operates in the Belgian market and focuses on innovation in the pharmaceutical sector.
Insider filings
Over the last 90 days, 2 filings published between 15 September and 12 October 2026: 2 open-market purchases by insiders for €497k. Largest amounts: Padilla Rafael (Member of administrative management or supervisory body), purchases of €397k; Bakker Vera (Senior executive), purchases of €100k.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 15 October 2026 (UTC)
Headquarters: Rotterdam, Netherlands · Founded: 2007 · Wikipedia article
Source: Wikidata (CC0).